No, I don’t think so. But, you did miss point from start:
Message 15856112
<<In addition since current treatment relies upon multiple drugs, testing this drug only against IV NTG does not tell the whole story.>>
Natrecor is not drug with single mechanism of action like diuretic, vasodilator (ACE or NTG), beta blockers, or inotropic (dubutamine), so it does not compete separately with each one. It does work in synergy with ACE and diuretics better than dobutamine or NTG. N benefit in acute PE (mild to severe cases) is apparent, and main contributions are:
-dilate veins and arteries, vasodilator
-stimulate the kidney to excrete excess fluid, diuretic,
-neutralize negative from excessive and harmful hormone secretion.
I will suggest that you read first AC transcript, last one (when it become available in few days), as well literature on N. It may help.
Miljenko
PS: I mentioned early that N will have hard time to penetrate market, and you are good example why. |
